Royalty Pharma Announces 13% Dividend Increase
January 08, 2021 08:00 ET
|
RP Management, LLC
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A...
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12
January 07, 2021 16:15 ET
|
RP Management, LLC
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January...
Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities
December 22, 2020 08:30 ET
|
RP Management, LLC
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller...
Royalty Pharma Announces Expansion of Leadership Team
December 21, 2020 08:12 ET
|
RP Management, LLC
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch, PhD will assume increased responsibilities with a new...
Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals
December 07, 2020 08:45 ET
|
RP Management, LLC
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today...
Royalty Pharma Reports Third Quarter 2020 Results
November 10, 2020 17:40 ET
|
RP Management, LLC
Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts(1)Increased 2020 guidance: Adjusted Cash Receipts(1) expected to be $1,780 to $1,800 million$2.3...
Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
November 02, 2020 07:30 ET
|
RP Management, LLC
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis...
Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
October 20, 2020 16:32 ET
|
RP Management, LLC
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary...
Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020
October 19, 2020 09:00 ET
|
RP Management, LLC
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S....
Royalty Pharma Announces Pricing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
October 15, 2020 23:45 ET
|
RP Management, LLC
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary...